JP2022542559A5 - - Google Patents

Info

Publication number
JP2022542559A5
JP2022542559A5 JP2022504107A JP2022504107A JP2022542559A5 JP 2022542559 A5 JP2022542559 A5 JP 2022542559A5 JP 2022504107 A JP2022504107 A JP 2022504107A JP 2022504107 A JP2022504107 A JP 2022504107A JP 2022542559 A5 JP2022542559 A5 JP 2022542559A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
domain
mage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022504107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542559A (ja
JP7721500B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043567 external-priority patent/WO2021016585A1/en
Publication of JP2022542559A publication Critical patent/JP2022542559A/ja
Publication of JP2022542559A5 publication Critical patent/JP2022542559A5/ja
Application granted granted Critical
Publication of JP7721500B2 publication Critical patent/JP7721500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022504107A 2019-07-24 2020-07-24 Mage-a4特異性を有するキメラ抗原受容体およびそれらの使用 Active JP7721500B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962878125P 2019-07-24 2019-07-24
US62/878,125 2019-07-24
US202063020177P 2020-05-05 2020-05-05
US63/020,177 2020-05-05
US202063021407P 2020-05-07 2020-05-07
US63/021,407 2020-05-07
PCT/US2020/043567 WO2021016585A1 (en) 2019-07-24 2020-07-24 Chimeric antigen receptors with mage-a4 specificity and uses thereof

Publications (3)

Publication Number Publication Date
JP2022542559A JP2022542559A (ja) 2022-10-05
JP2022542559A5 true JP2022542559A5 (cg-RX-API-DMAC7.html) 2023-07-31
JP7721500B2 JP7721500B2 (ja) 2025-08-12

Family

ID=72088367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504107A Active JP7721500B2 (ja) 2019-07-24 2020-07-24 Mage-a4特異性を有するキメラ抗原受容体およびそれらの使用

Country Status (14)

Country Link
US (1) US12600793B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004049A1 (cg-RX-API-DMAC7.html)
JP (1) JP7721500B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038397A (cg-RX-API-DMAC7.html)
CN (1) CN114174345B (cg-RX-API-DMAC7.html)
AU (1) AU2020316516A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001194A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147903A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000130A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000451A2 (cg-RX-API-DMAC7.html)
IL (1) IL289820A (cg-RX-API-DMAC7.html)
MX (1) MX2022000896A (cg-RX-API-DMAC7.html)
PH (1) PH12022550102A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021016585A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
JP7674278B2 (ja) 2019-07-03 2025-05-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ニューヨーク食道扁平上皮がん1(ny-eso-1)抗原結合タンパク質およびその使用方法
BR112022001194A2 (pt) * 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
WO2021226063A1 (en) 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) * 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
JP2024516308A (ja) * 2021-05-04 2024-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Mage-a4特異性を有するキメラ抗原受容体及びその使用
EP4370541A1 (en) * 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023004255A2 (en) * 2021-07-21 2023-01-26 Immunitybio, Inc. GENERATION OF CHIMERIC ANTIGEN RECEPTOR mRNA MOLECULES FOR EXPRESSION IN PRIMARY NK CELLS
EP4587046A1 (en) * 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
WO2000042185A1 (en) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methods for regulating the stability of recombinant proteins and products useful therein
ES2313886T3 (es) * 1999-03-16 2009-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv.
AU5275100A (en) * 1999-05-21 2000-12-12 Regents Of The University Of California, The Fluorescent protein indicators
AU6094100A (en) * 1999-07-13 2001-01-30 Heska Corporation Fc epsilon receptor-luminescence inducing protein chimeric nucleic acid molecules, fusion proteins and uses thereof
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US9708384B2 (en) * 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
ES2738705T3 (es) * 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MX2018001568A (es) * 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
BR112019010002A2 (pt) * 2016-12-16 2019-08-20 Merck Patent Gmbh métodos para o uso de proteína de ligação galectina-3 detectada na urina para monitoramento da gravidade e progressão da nefrite lúpica
ES2991091T3 (es) * 2017-06-05 2024-12-02 Univ Mie Proteína de unión a antígeno que reconoce el péptido derivado de MAGE-A4
BR112021006182A2 (pt) * 2018-10-01 2021-06-29 Adicet Bio, Inc. composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
BR112022001194A2 (pt) 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
MX2022001942A (es) 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
WO2021226063A1 (en) * 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
KR102777002B1 (ko) 항글리피칸-3 항체 및 이의 응용
CN115232209B (zh) 靶向gprc5d的抗体及其用途
KR20230098158A (ko) Cd7 표적의 인간화 항체 및 이의 용도
JP2021531004A5 (cg-RX-API-DMAC7.html)
JP2022548778A5 (cg-RX-API-DMAC7.html)
CN112639102A (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
WO2018108106A1 (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
JP2023171733A (ja) 新規抗pd-l1抗体
WO2018147245A1 (ja) 抗gprc5d抗体及び該抗体を含む分子
CN115403671B (zh) 靶向Claudin18.2的纳米抗体及其用途
JP2024508672A (ja) 新規抗cd24抗体
JP2023505415A (ja) 抗pd-l1/抗b7-h3多重特異性抗体及びその使用
JP2024516308A5 (cg-RX-API-DMAC7.html)
JP2025508343A5 (cg-RX-API-DMAC7.html)
WO2022057875A1 (zh) 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
WO2024001470A1 (zh) 靶向b7-h3的抗体及其用途
WO2025021027A1 (zh) 靶向人源cd7的抗体或其抗原结合片段及其应用
CN113825772B (zh) 抗her2亲合体及将其用作开关分子的可切换嵌合抗原受体
JP2022516627A (ja) プログラム細胞死リガンドに対する結合物およびその使用
JP2024105603A (ja) CARライブラリおよびscFvの製造方法
JP2024012258A (ja) Cd22に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
JP2021529539A5 (cg-RX-API-DMAC7.html)
CN116063527A (zh) 靶向间皮素的抗体及其用途